Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
CERE was delisted on the 31st of July, 2024.
125 hedge funds and large institutions have $4.23B invested in Cerevel Therapeutics Holdings, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 54 increasing their positions, 28 reducing their positions, and 14 closing their positions.
93% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 28
79% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 14
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
43% more call options, than puts
Call options by funds: $21.3M | Put options by funds: $14.9M
12% more capital invested
Capital invested by funds: $3.78B → $4.23B (+$443M)
10% more funds holding
Funds holding: 114 → 125 (+11)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$19.9M |
| 2 |
Barclays
London,
United Kingdom
|
+$10.1M |
| 3 |
BlackRock
New York
|
+$8.29M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$7.34M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$7.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$45.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$19.2M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$12.6M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$5.03M |
| 5 |
Alkeon Capital Management
New York
|
-$2.94M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IC
126
Ikarian Capital
Dallas,
Texas
| – | -$5.03M | -178,100 | Closed |
|
|
CC
127
Casdin Capital
New York
| – | -$2.26M | -80,000 | Closed |
|
128
BNP Paribas Financial Markets
Paris,
France
| – | -$1.75M | -61,985 | Closed |
|
|
TC
129
TwinBeech Capital
Purchase,
New York
| – | -$1.1M | -39,072 | Closed |
|
|
BFM
130
Boothbay Fund Management
New York
| – | -$960K | -33,959 | Closed |
|
|
HS
131
HighVista Strategies
Boston,
Massachusetts
| – | -$667K | -23,611 | Closed |
|
132
Verition Fund Management
Greenwich,
Connecticut
| – | -$550K | -19,457 | Closed |
|
|
C
133
Certuity
North Palm Beach,
Florida
| – | -$410K | -14,500 | Closed |
|
|
EGM
134
Engineers Gate Manager
New York
| – | -$216K | -7,638 | Closed |
|
135
Amundi
Paris,
France
| – | -$210K | -7,055 | Closed |
|
|
DFCM
136
Dark Forest Capital Management
San Juan,
Puerto Rico
| – | -$87K | -3,070 | Closed |
|
|
PHK
137
Point72 Hong Kong
Hong Kong
| – | -$42K | -1,470 | Closed |
|
|
CG
138
Cutler Group
San Francisco,
California
| – | -$28.2K | -1,000 | Closed |
|
|
HNWAG
139
High Net Worth Advisory Group
Naples,
Florida
| – | -$28K | -1,000 | Closed |
|
CERE Hedge Fund Activity: Q4 2022 in Review
125 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) for Q4 2022, worth a combined $4.23B — up 12% from $3.78B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new CERE positions and 14 closed out — a net gain of 11 holders — while 54 added to existing stakes and 28 trimmed.
The largest buyer was State Street, adding an estimated $19.9M. The largest seller was Janus Henderson Group, cutting an estimated $45.6M.
- 125 institutional investors held Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) as of Q4 2022, up from 114 in Q3 2022.
- Funds reported $4.23B of Cerevel Therapeutics Holdings, Inc. Common Stock stock for Q4 2022, up 12% quarter-over-quarter.
- 25 funds opened new Cerevel Therapeutics Holdings, Inc. Common Stock positions in Q4 2022 and 14 closed out, a net change of +11 holders.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock buyer in Q4 2022 was State Street, an estimated $19.9M added.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock seller in Q4 2022 was Janus Henderson Group, an estimated $45.6M sold.
Based on aggregated 13F filings for Q4 2022.